Zacks cuts Amneal Pharmaceuticals stock rating to Strong Sell
Published on 10/08/2026 at 16:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Zacks Research moved Amneal Pharmaceuticals from Hold to Strong Sell in a rating note reported on October 8, 2026.
- Second-quarter 2026 revenue reached USD 796.20 million, while adjusted earnings per share came in at USD 0.30 versus USD 0.24 consensus.
- Lang & Schwarz showed AMRX at EUR 17.10 on October 8, 2026, down 2.56 percent from EUR 17.55.
EUR 17.10 was the Lang & Schwarz price for Amneal Pharmaceuticals (ISIN US03168L1052) on October 8, 2026, at 4:35 p.m. CEST, down 2.56 percent versus the EUR 17.55 prior close on October 7. MarketBeat reported on October 8 that Zacks Research had cut Amneal from Hold to Strong Sell in a note issued Tuesday.
What the downgrade changes for valuation
The rating change contrasts with a wider analyst picture. MarketBeat cited nine Buy ratings and one Sell rating, alongside a consensus target of USD 21.00, while Amneal's market capitalization stood at USD 6.2 billion on October 8.
The currency gap matters for German investors: the USD target and the EUR Lang & Schwarz quote use different reference currencies and do not support a direct percentage comparison. The euro price itself fell 2.56 percent against its Lang & Schwarz prior close during the October 8 session.
Three milestones shape the earnings setup
On July 30, 2026, Amneal reported second-quarter revenue of USD 796.20 million and adjusted earnings per share of USD 0.30, above the USD 0.24 consensus cited by MarketBeat.
On September 18, 2026, Amneal announced FDA approval and the immediate launch of a 120 mg/0.5 mL lanreotide injection. The company linked the product to SOMATULINE Depot, whose U.S. annual sales reached USD 983 million in the 12 months ended July 2026, according to Amneal Pharmaceuticals.
On October 8, 2026, the Zacks move added a negative rating signal to a stock whose recent operating milestones included a second-quarter earnings beat and a new complex injectable launch.
Next reporting date is November 3
GlobeNewswire reported on October 8 that Amneal will publish third-quarter 2026 results on November 3, 2026, before the market opens, followed by an 8:30 a.m. ET webcast. That date gives the rating debate its next company-specific checkpoint.
At 4:35 p.m. CEST on October 8, 2026, Amneal Pharmaceuticals stock was trading at EUR 17.10 at Lang & Schwarz, down 2.56 percent versus the EUR 17.55 prior close on October 7. The further course of trading is shown by the continuously updated real-time quote of Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals stock facts
- Company: Amneal Pharmaceuticals, Inc.
- ISIN: US03168L1052
- Ticker: AMRX
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 8, 2026, 4:35 p.m. CEST: EUR 17.10
- Change versus prior close: minus 2.56 percent
- Prior close Lang & Schwarz October 7, 2026: EUR 17.55
- Market capitalization: USD 6.2 billion as of October 8, 2026
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
